{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:10:07Z","timestamp":1790802607514,"version":"4.1.0"},"reference-count":63,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Background: Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Modulator therapies have the ability to improve CFTR function in CF patients, but despite the clear evidence of benefits regarding CFTR modulator therapy, including improved lung function, the reduced rate of exacerbations, and an overall improved quality of life, studies focusing on the reduction rates of P. aeruginosa infections during modulator therapy expressed the need for future research on this topic. Objective: This study aimed to evaluate the impact of CFTR modulator therapies on the prevalence, density, and persistence of P. aeruginosa infection in CF patients and to explore the mechanisms involved. Methods: A systematic literature review was performed by searching five major databases (PubMed, Cochrane Library, Scopus, Google Scholar, and Web of Science), and 21 relevant articles investigating the link between CFTR therapy and P. aeruginosa infections were selected following the PRISMA guidelines. Results: The data indicated that Ivacaftor and the combination Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) can reduce total bacterial load and markers of systemic inflammation. However, clonal lines of P. aeruginosa persist in most cases, and complete eradication is rare, mainly due to biofilm formation and antimicrobial resistance. Conclusions: Although CFTR-modulating therapies help to improve clinical condition and reduce inflammation, they do not consistently lead to the elimination of P. aeruginosa.<\/jats:p>","DOI":"10.3390\/idr17040080","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:19:27Z","timestamp":1751887167000},"page":"80","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effects of CFTR Modulators on Pseudomonas aeruginosa Infections in Cystic Fibrosis"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7573-3714","authenticated-orcid":false,"given":"Camelia Corina","family":"Pescaru","sequence":"first","affiliation":[{"name":"Center for Research and Innovation in Personalized Medicine of Respiratory Diseases (CRIPMRD), \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Pulmonary Rehabilitation Center, Clinical Hospital of Infectious Diseases and Pulmonology, \u201cVictor Babes\u201d, Gheorghe Adam Street 13, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6020-4593","authenticated-orcid":false,"given":"Alexandru Florian","family":"Cri\u0219an","sequence":"additional","affiliation":[{"name":"Pulmonary Rehabilitation Center, Clinical Hospital of Infectious Diseases and Pulmonology, \u201cVictor Babes\u201d, Gheorghe Adam Street 13, 300310 Timisoara, Romania"},{"name":"Research Center for Assessment of Human Motion, Functionality and Disability, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2112-2923","authenticated-orcid":false,"given":"Adelina","family":"Mari\u021bescu","sequence":"additional","affiliation":[{"name":"Pulmonary Rehabilitation Center, Clinical Hospital of Infectious Diseases and Pulmonology, \u201cVictor Babes\u201d, Gheorghe Adam Street 13, 300310 Timisoara, Romania"},{"name":"Doctoral School, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"C\u0103runta","sequence":"additional","affiliation":[{"name":"Pulmonary Rehabilitation Center, Clinical Hospital of Infectious Diseases and Pulmonology, \u201cVictor Babes\u201d, Gheorghe Adam Street 13, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1160-9164","authenticated-orcid":false,"given":"Monica","family":"Marc","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation in Personalized Medicine of Respiratory Diseases (CRIPMRD), \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Pulmonology Clinic, Clinical Hospital of Infectious Diseases and Pulmonology, \u201cVictor Babes\u201d, Gheorghe Adam Street 13, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0218tefan","family":"Dumitrache-Rujinski","sequence":"additional","affiliation":[{"name":"Pulmonology Department, University of Medicine and Pharmacy \u201cCarol Davila\u201d, Dionisie Lupu nr.37, Sector 1 Bucharest, 030167 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5436-5158","authenticated-orcid":false,"given":"Sorina","family":"Laitin","sequence":"additional","affiliation":[{"name":"Epidemiology University Clinic, Department XIII, \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Epidemiology Department, Clinical Hospital of Infectious Diseases and Pulmonology, \u201cVictor Babes\u201d, Gheorghe Adam Street 13, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Oancea","sequence":"additional","affiliation":[{"name":"Center for Research and Innovation in Personalized Medicine of Respiratory Diseases (CRIPMRD), \u201cVictor Babes\u201d University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania"},{"name":"Pulmonology Clinic, Clinical Hospital of Infectious Diseases and Pulmonology, \u201cVictor Babes\u201d, Gheorghe Adam Street 13, 300310 Timisoara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: A disease with a new face","volume":"109","year":"2020","journal-title":"Acta Paediatr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jurado-Mart\u00edn, I., Sainz-Mej\u00edas, M., and McClean, S. (2021). Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063128"},{"key":"ref_5","unstructured":"World Health Organization (2024). World Health Organization Bacterial Priority List, World Health Organization."},{"key":"ref_6","first-page":"e000167","article-title":"Transmission and lineage displacement drive rapid population genomic flux in cystic fibrosis airway infections of a Pseudomonas aeruginosa epidemic strain","volume":"4","author":"Williams","year":"2018","journal-title":"Microb. Genom."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in epithelial physiology","volume":"74","author":"Gray","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lopes-Pacheco, M. (2016). CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00275"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lopes-Pacheco, M. (2020). CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01662"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1164\/rccm.202305-0844LE","article-title":"Cell-Free DNA Detects Pseudomonas aeruginosa Lung Infection in Modulator-treated People with Cystic Fibrosis","volume":"208","author":"Long","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e15756","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor\u2014Tezacaftor\u2014Ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","first-page":"1694","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"395","author":"Heijerman","year":"2020","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2022.12.009","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on annual rate of lung function decline in people with cystic fibrosis","volume":"22","author":"Lee","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: Real-world evidence from the German CF Registry","volume":"32","author":"Sutharsan","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Durfey, S.L., Pipavath, S., Li, A., Vo, A.T., Ratjen, A., Carter, S., Morgan, S.J., Radey, M.C., Grogan, B., and Salipante, S.J. (2021). Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections. mBio, 12.","DOI":"10.1128\/mbio.03148-21"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Armbruster, C.R., Hilliam, Y.K., Zemke, A.C., Atteih, S., Marshall, C.W., Moore, J., Koirala, J., Krainz, L., Gaston, J.R., and Lee, S.E. (2024). Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis. mBio, 15.","DOI":"10.1128\/mbio.00519-24"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jcf.2018.03.010","article-title":"CFTR rescue with VX-809 and VX-770 favors the repair of primary airway epithelial cell cultures from patients with class II mutations in the presence of Pseudomonas aeruginosa exoproducts","volume":"17","author":"Adam","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1093\/infdis\/jiae051","article-title":"Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis","volume":"230","author":"Ledger","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jcf.2014.09.013","article-title":"Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients","volume":"14","author":"Yau","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcf.2021.05.001","article-title":"Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis","volume":"20","author":"Beckert","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Eschenhagen, P.N., Bacher, P., Grehn, C., Mainz, J.G., Scheffold, A., and Schwarz, C. (2023). Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in cystic fibrosis decreases after initiation of highly effective CFTR modulator therapy. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1180826"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"00687-2023","DOI":"10.1183\/23120541.00687-2023","article-title":"Impact of CFTR modulators on exercise capacity in adolescents with cystic fibrosis","volume":"10","author":"Ahmed","year":"2024","journal-title":"ERJ Open Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Migliorisi, G., Collura, M., Ficili, F., Pensabene, T., Bongiorno, D., Collura, A., Di Bernardo, F., and Stefani, S. (2022). Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study. Pharmaceuticals, 15.","DOI":"10.20944\/preprints202204.0114.v1"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cigana, C., Giannella, R., Colavolpe, A., Alcal\u00e1-Franco, B., Mancini, G., Colombi, F., Bigogno, C., Bastrup, U., Bertoni, G., and Bragonzi, A. (2023). Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.04083-22"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Luscher, A., Simonin, J., Falconnet, L., Valot, B., Hocquet, D., Chanson, M., Resch, G., K\u00f6hler, T., and van Delden, C. (2020). Combined Bacteriophage and Antibiotic Treatment Prevents Pseudomonas aeruginosa Infection of Wild Type and cftr- Epithelial Cells. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.01947"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Aspinall, S.A., Mackintosh, K.A., Hill, D.M., Cope, B., and McNarry, M.A. (2022). Evaluating the Effect of Kaftrio on Perspectives of Health and Wellbeing in Individuals with Cystic Fibrosis. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19106114"},{"key":"ref_31","unstructured":"Aromataris, E., and Munn, Z. (2020). JBI Manual for Evidence Synthesis, Joanna Briggs Institute."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of Reccomandation","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Petrova, N., Balinova, N., Marakhonov, A., Vasilyeva, T., Kashirskaya, N., Galkina, V., Ginter, E., Kutsev, S., and Zinchenko, R. (2021). Ethnic Differences in the Frequency of CFTR Gene Mutations in Populations of the European and North Caucasian Part of the Russian Federation. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.678374"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"Zolin","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100434","DOI":"10.1016\/j.lansea.2024.100434","article-title":"CFTR mutations and phenotypic correlations in people with cystic fibrosis: A retrospective study from a single centre in south India","volume":"27","author":"Varkki","year":"2024","journal-title":"Lancet Reg. Health Southeast Asia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kapouni, N., Moustaki, M., Douros, K., and Loukou, I. (2023). Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. Children, 10.","DOI":"10.3390\/children10030554"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Bacalhau, M., Camargo, M., Magalh\u00e3es-Ghiotto, G.A.V., Drumond, S., Castelletti, C.H.M., and Lopes-Pacheco, M. (2023). Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030410"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Valladares, K.N., Jones, L.I., Barnes, J.W., and Krick, S. (2024). Highly Effective Modulator Therapy: Implications for the Microbial Landscape in Cystic Fibrosis. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252211865"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e002049","DOI":"10.1136\/bmjresp-2023-002049","article-title":"Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy","volume":"11","author":"Burgel","year":"2024","journal-title":"BMJ Open Respir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1002\/ppul.24364","article-title":"Anti-inflammatories and mucociliary clearance therapies in the age of CFTR modulators","volume":"54","author":"Perrem","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Chung, J., Eisha, S., Park, S., Morris, A.J., and Martin, I. (2023). How Three Self-Secreted Biofilm Exopolysaccharides of Pseudomonas aeruginosa, Psl, Pel, and Alginate, Can Each Be Exploited for Antibiotic Adjuvant Effects in Cystic Fibrosis Lung Infection. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24108709"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/9781555817466.ch11","article-title":"Bacterial Extracellular Polysaccharides in Biofilm Formation and Function","volume":"3","author":"Limoli","year":"2015","journal-title":"Microb. Biofilms"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Santos-Fernandez, E., Martin-Souto, L., Antoran, A., Areitio, M., Aparicio-Fernandez, L., Bouchara, J.P., Schwarz, C., Rementeria, A., Buldain, I., and Ramirez-Garcia, A. (2023). Microbiota and fungal-bacterial interactions in the cystic fibrosis lung. FEMS Microbiol Rev., 47.","DOI":"10.1093\/femsre\/fuad029"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Thi, M.T.T., Wibowo, D., and Rehm, B.H.A. (2020). Pseudomonas aeruginosa Biofilms. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228671"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.tim.2016.01.008","article-title":"Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections","volume":"24","author":"Winstanley","year":"2016","journal-title":"Trends Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Soares, A., Alexandre, K., and Etienne, M. (2020). Tolerance and Persistence of Pseudomonas aeruginosa in Biofilms Exposed to Antibiotics: Molecular Mechanisms, Antibiotic Strategies and Therapeutic Perspectives. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.02057"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Moser, C., Jensen, P.\u00d8., Thomsen, K., Kolpen, M., Rybtke, M., Lauland, A.S., Tr\u00f8strup, H., and Tolker-Nielsen, T. (2021). Immune Responses to Pseudomonas aeruginosa Biofilm Infections. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.625597"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Jarzynka, S., Makarewicz, O., Weiss, D., Minkiewicz-Zochniak, A., Iwa\u0144ska, A., Skorupa, W., Padzik, M., Augustynowicz-Kope\u0107, E., and Ol\u0119dzka, G. (2023). The Impact of Pseudomonas aeruginosa Infection in Adult Cystic Fibrosis Patients\u2014A Single Polish Centre Study. Pathogens, 12.","DOI":"10.3390\/pathogens12121440"},{"key":"ref_51","first-page":"e40","article-title":"The future of cystic fibrosis care: A global perspective","volume":"7","author":"Bell","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: The 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17460441.2021.1912732","article-title":"Discovery of CFTR modulators for the treatment of cystic fibrosis","volume":"16","author":"Pedemonte","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/ppul.24424","article-title":"Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations","volume":"54","author":"Salvatore","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"00031-2022","DOI":"10.1183\/23120541.00031-2022","article-title":"Chronic cough in cystic fibrosis: The effect of modulator therapy on objective 24-h cough monitoring","volume":"8","author":"Zhang","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jcf.2018.04.004","article-title":"Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations","volume":"18","author":"Guimbellot","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1513\/AnnalsATS.202010-1336SD","article-title":"Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design","volume":"18","author":"Nichols","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Dobi\u00e1\u0161, R., \u0160kr\u00edba, A., Pluh\u00e1\u010dek, T., Pet\u0159\u00edk, M., Palyzov\u00e1, A., K\u00e1\u0148ov\u00e1, M., \u010cubov\u00e1, E., Hou\u0161\u0165, J., Nov\u00e1k, J., and Stevens, D.A. (2021). Noninvasive Combined Diagnosis and Monitoring of Aspergillus and Pseudomonas Infections: Proof of Concept. J. Fungi, 7.","DOI":"10.3390\/jof7090730"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2213-2600(24)00407-7","article-title":"Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): An analysis from a single-arm, phase 3 trial","volume":"13","author":"Hoppe","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: Randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): Results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir. Med."}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/17\/4\/80\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:06:00Z","timestamp":1760033160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/17\/4\/80"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["idr17040080"],"URL":"https:\/\/doi.org\/10.3390\/idr17040080","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}